济民健康：11月13日召开董事会会议

Group 1 - The core point of the article is that Jimin Health (SH 603222) held its 23rd meeting of the fifth board of directors on November 13, 2025, to review proposals regarding the formulation and revision of certain management systems [1] - For the first half of 2025, Jimin Health's revenue composition was as follows: pharmaceutical manufacturing accounted for 52.07%, medical services for 46.01%, pharmaceutical trading for 1.54%, and other businesses for 0.38% [1] - As of the time of reporting, Jimin Health's market capitalization was 6 billion yuan [1]